个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 自然指数

作者：
Hu, Xichun[1] * ; Zhang, Qingyuan[2] * ; Sun, Tao[3] ; Xiong, Huihua[4] ; Li, Wei[5] ; Teng, Yuee[6] ; Lu, Yen-Shen[7] ; Tseng, Ling-Ming[8] ; Yan, Min[9] ; Li, Hongsheng[10] ; Pang, Danmei[11] ; -Chen, Shin-Cheh[12] ; Chen, Wenyan[13] ; Jiang, Ou[14] ; Wang, Jingfen[15] ; Wu, Xinhong[16] ; Wang, Xian[17] ; Zang, Aimin[18] ; Wang, Xiaojia[19] ; Collins, Julie M.[20] ; Fan, Ethan[21] ; Jiang, Lin[21] ; Zeng, Xiaoling[21] ; Turner, Nicholas C.[22] ;
机构： [1]Fudan Univ, Fudan Univ Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China [2]Harbin Med Univ Canc Hosp, Harbin, Peoples R China [3]Liaoning Canc Hosp, Shenyang, Liaoning, Peoples R China [4]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [5]First Hosp Jilin Univ, Changchun, Peoples R China [6]First Hosp China Med Univ, Shenyang, Liaoning, Peoples R China [7]Natl Taiwan Univ Hosp, Taipei, Taiwan [8]Taipei Vet Gen Hosp, Taipei, Taiwan [9]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China [10]Guangzhou Med Univ, Affiliated Tumor Hosp, Guangzhou, Peoples R China [11]First Peoples Hosp Foshan, Foshan, Peoples R China [12]Linkou Chang Gung Mem Hosp, Div Breast Surg, Taoyuan, Taiwan [13]Third Hosp Nanchang, Nanchang, Peoples R China [14]Second Peoples Hosp Neijiang, Neijiang, Peoples R China [15]Linyi Canc Hosp, Linyi, Peoples R China [16]Tongji Med Coll, Hubei Canc Hosp, Dept Breast Surg, Wuhan, Hubei, Peoples R China [17]Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China [18]Affiliated Hosp Hebei Univ, Baoding, Hebei, Peoples R China [19]Zhejiang Canc Hosp, Hangzhou, Peoples R China [20]AstraZeneca, Oncol R&D, Gaithersburg, MD USA [21]AstraZeneca, Oncol R&D, Shanghai, Peoples R China [22]Royal Marsden Hosp, Inst Canc Res, London, England
出处：
DOI： 10.1038/s41467-025-59210-6
ISSN：

摘要：
In the global CAPItello-291 randomized phase 3 study (NCT04305496) in patients with hormone receptor-positive/HER2-negative advanced breast cancer and progression during/after aromatase inhibitor treatment, capivasertib-fulvestrant significantly improved progression-free survival (PFS) in the overall population and patients with PIK3CA/AKT1/PTEN-altered tumors versus placebo-fulvestrant. We assessed efficacy and safety of capivasertib-fulvestrant in a prespecified exploratory analysis of a Chinese cohort (n = 24) and extended study with the same protocol (n = 110). Clinically meaningful PFS benefit for capivasertib-fulvestrant was observed in the overall population (median PFS: 6.9 [capivasertib-fulvestrant] versus 2.8 [placebo-fulvestrant] months; hazard ratio 0.51, 95% CI 0.34-0.76), patients with PIK3CA/AKT1/PTEN-altered tumors (n = 46; 5.7 versus 1.9 months; hazard ratio 0.41, 95% CI 0.19-0.85) and PIK3CA/AKT1/PTEN-non-altered tumors (patients with confirmed next-generation sequencing results [n = 68]; 9.2 versus 2.7 months; hazard ratio 0.38; 95% CI 0.21-0.68). The most frequent adverse events (AEs) with capivasertib-fulvestrant were diarrhea (60.6% versus 11.3% with placebo-fulvestrant) and hyperglycemia (57.7% versus 17.7%). AEs leading to capivasertib-fulvestrant discontinuation were reported in 11.3% of patients versus 3.2% for placebo-fulvestrant. The benefit-risk profile of capivasertib-fulvestrant in the Chinese cohort was favorable; further exploration in patients with PIK3CA/AKT1/PTEN-non-altered tumors is warranted.

基金：
AstraZeneca; Stavroula Bitsi, PhD, of BOLDSCIENCE Ltd - AstraZeneca
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2026]版：
无
最新[2025]版：
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
JCR分区：
出版当年[2025]版：
无
最新[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 最新[2023版] 最新五年平均 出版当年[2025版] 出版当年五年平均 出版前一年[2024版]

第一作者：
第一作者机构： [1]Fudan Univ, Fudan Univ Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Hu Xichun,Zhang Qingyuan,Sun Tao,et al.Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort[J].NATURE COMMUNICATIONS.2025,16(1):doi:10.1038/s41467-025-59210-6.
APA：
Hu, Xichun,Zhang, Qingyuan,Sun, Tao,Xiong, Huihua,Li, Wei...&Turner, Nicholas C..(2025).Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.NATURE COMMUNICATIONS,16,(1)
MLA：
Hu, Xichun,et al."Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort".NATURE COMMUNICATIONS 16..1(2025)

资源点击量：15709 今日访问量：3 总访问量：1038 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持：重庆聚合科技有限公司 地址：保定市莲池区裕华东路212号